China approves use of Pfizer's Covid drug Paxlovid
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[BEIJING] China's medical products regulator said on Saturday (Feb 12) it has given conditional approval for Pfizer's Covid-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.
The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate Covid-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.
It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
South-east Asian markets account for 8.8% of global capital inflows from 2021 to 2024: report
